사이오나 테라퓨틱스(SION)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $5.96 (-16.99%), 시가총액 $1.93B, 52주 최저~최고 $12.72 ~ $45.95.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in P
사이오나 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
사이오나 테라퓨틱스의 현재 주가는 $5.96 (-16.99%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
사이오나 테라퓨틱스의 시가총액은 약 $1.93B입니다.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane